A multicenter trial with blinded endpoint evaluation was conducted in patients hospitalized for moderate or severe ulcerative colitis. Twenty-five patients were randomized to receive heparin as a continuous infusion or methylprednisolone (0.75-1 mg/kg/day). 13 patients received methylprednisolone and 12 received heparin.
Significant improvement or remission at day 10:
By day 10, 69% of patients in the methylprednisolone group, but none in the heparin group, achieved significant improvement or remission. Additionally, C-reactive protein levels decreased significantly in the methylprednisolone group, but not in the heparin group.
Three patients in the heparin group were withdrawn before day 10 due to severe rectal bleeding needing transfusion (2 cases) or surgery (1 case). The proportion of patients with persistent rectal bleeding at day 10 was 31% in the methylprednisolone group, and 90% in the heparin group (P < 0.05).